NULIBRY is a first-in-class synthetic cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A
WINREVAIR is a breakthrough biologic for this rare, progressive disease
With just few days of treatment, the patient started responding well and finally complete clinical resolution of infection was attained
The talk show will be held monthly via Medanta's YouTube, Facebook and LinkedIn channe
MASH is a chronic and progressive liver disease characterised by fat accumulation and inflammation in the liver,
The initiative, “Change the Odds: Uniting to Improve Cancer Outcomes” aims to enhance awareness of and access to cancer screening, clinical trials and support
Indian Pharma Post brings together the views of industry leaders on the Interim Union Budget 2024-25 announcement and its impact on the industry
The congress aims at emphasizing on the most recent trends, advancements in the field of Obstetrics & Gynaecology
The findings of Phase 3 study are in line with Phase 2 study conducted in the US and Europe
Extraintestinal pathogenic E. coli (ExPEC) has been identified as the leading bacterial cause of sepsis
Subscribe To Our Newsletter & Stay Updated
